ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Nov 09, 2020 09:08 JST
Source:
Eisai
Eisai: Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood
- The Content Presented at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference -
TOKYO, Nov 09, 2020 - (JCN Newswire) - Sysmex Corporation and Eisai Co., Ltd. announced that the most recent data from the project to develop a method of diagnosing Alzheimer's disease (AD) using blood plasma was presented at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference, held virtually from November 4 to 7, 2020. Sysmex demonstrated on behalf of the two companies the performance of the amyloid beta (Abeta) in plasma measured on Sysmex's HISCLTM fully automated immunoassay analyzers in predicting amyloid pathology as defined by amyloid positron emission tomography (PET) imaging on the centiloid scale.(1)
The total number of those living with dementia across the world is projected to reach 82 million in 2030 and 152 million in 2050, with the total global societal cost of dementia stemming from direct medical and social care costs and lower productivity being estimated to reach 2 trillion USD in 2030.(6) In Japan, the number of those with dementia is thought to have reached approximately 4.62 million in 2012 and is projected to grow to 7.30 million in 20257, with the total societal cost of this disease is estimated to be equivalent to 4.1%8 of the gross domestic product (GDP) in 2025 (25.8 trillion yen9). Of these sufferers, those living with AD are thought to account for more than 60% of those living with dementia.(7)
It is conceivable that AD is a disease that results in synaptic dysfunction and neuronal cell death due to tau deposition in neurons triggered by Abeta aggregation on the outside of neurons. These brain changes cause cognitive impairment and psychological and behavioral symptoms, suggesting that the Abeta aggregation and accumulation inside the brain is caused by AD before the presence of cognitive impairment appears, thus, it is believed that early diagnosis and early intervention is more effective in therapies targeting Abeta. Currently, amyloid PET and Abeta ratio in cerebrospinal fluid (CSF) are used for detecting amyloid aggregates in the brain, but this puts a significant burden on patients in terms of access, costs, and their physical wellbeing.(10)
Sysmex and Eisai are working to create new diagnostic technologies for the prevention and treatment of dementia. Accordingly, the overarching aim is to contribute to the advancement of healthcare and improve the quality of life for those living with the disease and their families.
Terminology
(1) A standardization scale for integration analysis of PET SUVR values as measured by different amyloid PET imaging probes.
(2) Trained doctors qualitatively distinguish amyloid PET positive from amyloid negative subjects by visually reading images.
(3) Klunk WE et al, Alzheimer's Dementia (2014)
(4) Assesses how correlated two sets of data are based on two quantitative data distributions.
For the purpose of this analysis, Spearman's rank correlation coefficient (rs), which is a
correlation index as determined by the rankings of the two variables, was calculated.
(5) Schindler SE et al, Neurology (2019)
(6) World Alzheimer Report 2018
(7) Promotion of Comprehensive Measures against Dementia, Ministry of Health, Labour and
Welfare
(8) Study on Economic Impact of Dementia in Japan, 2014 Health Labour Sciences Research
Grant Annual Report
(9) Estimated by Sysmex based on Japan's Medium-term Economic Outlook (February 2018),
Daiwa Institute of Research
(10) Abeta is a peptide made of amino-acid residues removed from amyloid precursor protein. Many of them are Abeta1-40, which is comprised of 40-residues, and the Abeta1-40 level does not fluctuate significantly as AD progresses. Comprised of 42-residues, Abeta1-42, on the other hand, is highly cohesive and decreases in cerebrospinal fluid (CSF) from the early stages of AD. It is believed that Abeta's absolute values show individual and intrinsic variability but that the plasma Abeta1-42/Abeta1-40 ratio remains unchanged. It has also been reported that the plasma Abeta1-42/Abeta1-40 ratio in CSF shows a high correlation with amyloid PET.
About the collaboration between Sysmex and Eisai
In February 2016, Sysmex and Eisai signed a comprehensive non-exclusive agreement aimed at the development of new diagnostic tests in the field of dementia. By leveraging each other's technologies and knowledge, the objective has been to discover next-generation diagnostic reagents that will enable early diagnosis of dementia, selection of the most appropriate treatment options, and regular monitoring of the effects of such treatments. At the 12th CTAD held in December 2019, the two companies reported on the performance of the plasma Abeta ratio measured on a fully automated immunoassay system HISCL in predicting the amyloid PET scan results (sensitivity: 73%, specificity: 71% [AUC = 0.74]), thus demonstrating the potential to predict amyloid pathology in the brain using the plasma Abeta ratio.* This finding was expected to lead to the development of a simple method of diagnosing Alzheimer's disease using blood.
*
https://www.sysmex.co.jp/en/news/2019/191209.html
https://www.eisai.com/news/2019/news201990.html
Source: Eisai
Sectors: BioTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 10:53 JST
All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating
Apr 18, 2024 09:22 JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 17, 2024 16:17 JST
Honda Unveils Next-generation EV Series for China
Apr 17, 2024 12:15 JST
Lexus presents Time at the 2024 Milan Design Week
Apr 16, 2024 18:49 JST
Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA
Apr 16, 2024 14:36 JST
New circuit challenge for TOYOTA GAZOO Racing
Apr 15, 2024 17:21 JST
TOYOTA GAZOO Racing back on asphalt for Croatian challenge
Apr 12, 2024 19:36 JST
Heidelberg Materials North America Announces Latest Milestone in Edmonton CCUS Project
Apr 12, 2024 14:39 JST
MHIAEL Completes Expansion of the its Nagasaki Plant for Manufacture of Aero Engine Combustors
Apr 11, 2024 18:08 JST
More Latest Release >>
Related Release
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
4/18/2024 10:53:00 AM JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
4/17/2024 4:17:00 PM JST
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
4/3/2024 4:24:00 PM JST
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
4/1/2024 9:39:00 AM JST
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
3/29/2024 3:51:00 PM JST
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
3/29/2024 3:19:00 PM JST
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
3/29/2024 2:32:00 PM JST
Lifenet and Eisai Co-Develop Dementia Insurance "be"
3/21/2024 5:36:00 PM JST
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
3/21/2024 4:10:00 PM JST
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
3/6/2024 5:47:00 PM JST
More Press release >>